Pharma’s R&D Ambitions Go Global
India’s life sciences R&D is undergoing a sea change. Given the huge risks and investments involved, can India taste success in innovative medicine, therapy and diagnostic tools?
bharat biotech
April 2023
January 2023
December 2022
November 2022
September 2022
June 2022
May 2022
April 2022
India's first nasal Covid vaccine iNCOVACC launched; priced at ₹325/dose
Bharat Biotech’s vaccine dubbed as “game changer”; to offer efficient distribution and easy and pain-free administration.
COVAXIN successfully completes phase 2/3 trials in U.S.
The results show no adverse effects were seen in clinical trials; the company says the vaccine is an alternative for those hesitant to receive mRNA jabs in the U.S.
Bharat Biotech's Covid-19 nasal vaccine to cost ₹800 in pvt market, ₹325 for govt supplies
The iNCOVACC vaccine received Indian drug regulator's approval to be used as a booster dose for the adult population.
Bharat Biotech's intranasal Covid-19 vaccine to be available on Co-WIN app from today
The vaccine will be available on the Co-WIN platform for persons aged above 18 years for primary 2 dose schedule, homologous booster doses, from Friday evening.
Bharat Biotech’s intra-nasal vaccine approved as primary, heterologous booster
iNCOVACC becomes the world’s first intranasal vaccine to receive both primary series and heterologous booster approval.
Bharat Biotech's intranasal Covid-19 vaccine approved for restricted use
It’s India's first nasal vaccine against Covid-19. Health minister Mansukh Mandaviya says it’ll further strengthen country's fight against pandemic
COVAXIN shows safety, immunogenicity in children aged 2-18 years: Lancet
Peer-reviewed data has been published in Lancet Infectious Diseases; phase II-III study was held to evaluate safety, and immunogenicity of COVAXIN among healthy children and adolescents.
$19.3 million to Bharat Biotech consortium for ‘variant-proof’ Covid vaccine
The funding seeks to establish preclinical and clinical proof of concept for a vaccine designed to provide protection against all known SARS-CoV-2 variants.
Covaxin, Corbevax get 'emergency use' nod for kids aged 5-12
The CDSCO approval has also been granted for two doses of ZyCov-D for those aged over 12. The decision comes amid a rise in Covid cases in cities like Delhi.
